The physician evaluates contraindications and comorbidities, discusses treatment goals, and selects an appropriate GLP-1 or alternative therapy with a titration schedule tailored to tolerability and efficacy
Lower doses may be reasonable for some patients, but microdosing is still off-label, and the strongest evidence still comes from standard therapeutic dosing in populations with clinical obesity or metabolic disease, and many of the broader claims around low-dose use exceed what the evidence supports
This dysregulation is secondary to mutations in elements of the pathway that include the APC gene (adenomatous polyposis coli), -catenin, or other elements, which make the pathway to be constitutively active and has oncogenic consequences [118, 119]
2.4 In vitro cell culture Caco-2 cells (passage #51) were cultured in DMEM (supplemented with 10% FBS) for 3 days on plastic coverslips at the bottom of 1 mL wells in 24-well cluster plates at a density of 1 10 6 cells/mL